Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Tuesday, Oppenheimer analysts reiterated their Outperform rating on Revolution stock, maintaining a price target of $75.00, well above the current trading price of $40.65. The stock has shown strong momentum with a nearly 10% gain over the past week. The reaffirmation comes amid updates from competing KRAS programs presented at this year’s ASCO conference. According to InvestingPro data, analyst targets range from $57 to $88, reflecting strong institutional confidence in the company’s potential.
Revolution, listed on NASDAQ under the ticker RVMD, has been relatively quiet at the event, following a recent comprehensive update on its pipeline. With a market capitalization of $7.57 billion and a strong balance sheet showing more cash than debt, the company continues to focus on its clinical programs across various indications, which the analysts believe support its best-in-class portfolio. For deeper insights into Revolution’s financial health and growth prospects, InvestingPro subscribers have access to over 30 additional financial metrics and analyst recommendations.
The Oppenheimer analysts noted that Revolution’s competitors in the G12Di space for pancreatic ductal adenocarcinoma (PDAC) may face challenges due to smaller datasets. Meanwhile, Revolution’s Phase 3 trials in second-line and beyond non-small cell lung cancer (NSCLC) and PDAC are actively recruiting.
Attention is now shifting to front-line opportunities, as registrational trials in first-line metastatic PDAC and the adjuvant setting are being initiated. The analysts anticipate potential pipeline updates in the second half of the year that could further inform Revolution’s development strategy.
In other recent news, Revolution Medicines has initiated a Phase 3 clinical trial for its drug daraxonrasib, targeting non-small cell lung cancer (NSCLC) with specific RAS mutations. The trial, named RASolve 301, aims to compare the efficacy and safety of daraxonrasib against traditional chemotherapy in patients with advanced NSCLC. Additionally, Revolution Medicines reported a strong cash position of $2.1 billion at the end of Q1 2025, despite a net loss of $213.4 million, which the company attributes to increased R&D expenses. The company is advancing its cancer treatment pipeline, focusing on developing its RAS inhibitor portfolio, including daraxonrasib, which is also being tested for pancreatic cancer. H.C. Wainwright recently adjusted the price target for Revolution Medicines to $72, maintaining a Buy rating, following promising clinical data on elironrasib monotherapy for NSCLC. The company is also expanding its commercial capabilities in the U.S., with plans to introduce additional RAS(ON) inhibitors targeting different oncogenic RAS mutations. These developments reflect Revolution Medicines’ ongoing efforts to establish its RAS inhibitors as leading therapies in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.